Medtronic (BUE:MDT) Cyclically Adjusted Revenue per Share: ARS10,347.34 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:MDT Medtronic PLC BUE:MDT
66 GF Score
Price ARS32,520.00
GF Value ARS38,174.99
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medtronic Cyclically Adjusted Revenue per Share?

Medtronic BUE:MDT +1.18% 66 Cyclically Adjusted Revenue per Share is ARS10,347.34 as of Apr. 2026. GuruFocus rates BUE:MDT with a GF Score™ of 66/100 and a GF Value™ of ARS38,174.99 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medtronic's adjusted revenue per share for the three months ended in Apr. 2026 was ARS21,185.726. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS10,347.34 for the trailing ten years ended in Apr. 2026.

During the past 12 months, Medtronic's average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Medtronic was 17.40% per year. The lowest was 4.20% per year. And the median was 9.10% per year.

As of today (2026-07-24), Medtronic's current stock price is ARS32520.00. Medtronic's Cyclically Adjusted Revenue per Share for the quarter that ended in Apr. 2026 was ARS10,347.34. Medtronic's Cyclically Adjusted PS Ratio of today is 3.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medtronic was 6.71. The lowest was 2.68. And the median was 4.80.


Medtronic  (BUE:MDT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medtronic's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32520.00/10347.34
=3.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medtronic was 6.71. The lowest was 2.68. And the median was 4.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medtronic Cyclically Adjusted Revenue per Share Related Terms


Medtronic Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medtronic's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtronic Cyclically Adjusted Revenue per Share Chart

Medtronic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,156.45 2,763.37 6,951.61 7,864.02 10,347.34

Medtronic Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,864.02 8,996.77 10,116.04 10,011.34 10,347.34

BUE:MDT vs SYK, BSX, EW: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Medtronic's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medtronic Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medtronic's Cyclically Adjusted PS Ratio falls into.


BUE:MDT
66GF Score
Medtronic PLC BUE:MDT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtronic Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medtronic's adjusted Revenue per Share data for the three months ended in Apr. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=21185.726/128.4300*128.4300
=21,185.726

Current CPI (Apr. 2026) = 128.4300.

Medtronic Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201607 153.062 100.872 194.878
201610 161.880 99.776 208.370
201701 167.865 99.178 217.377
201704 176.490 100.773 224.929
201707 191.277 100.673 244.015
201710 182.625 100.374 233.672
201801 213.630 99.377 276.085
201804 239.759 100.374 306.776
201807 312.363 101.470 395.355
201810 453.829 101.271 575.538
201901 419.702 100.075 538.620
201904 521.730 102.068 656.480
201907 470.775 101.969 592.944
201910 656.772 101.969 827.208
202001 683.595 101.371 866.072
202004 572.861 101.969 721.522
202007 679.716 101.570 859.466
202010 862.373 100.474 1,102.326
202101 964.192 101.171 1,223.977
202104 1,107.065 103.065 1,379.521
202107 1,127.743 103.763 1,395.838
202110 1,143.729 105.557 1,391.563
202201 1,180.634 106.255 1,427.032
202204 1,337.673 110.242 1,558.370
202207 1,385.273 113.262 1,570.785
202210 1,677.697 115.315 1,868.506
202301 2,051.818 114.470 2,302.050
202304 2,267.667 118.213 2,463.661
202307 2,964.618 119.903 3,175.439
202310 4,196.111 121.111 4,449.695
202401 9,821.359 119.179 10,583.729
202404 11,128.712 121.232 11,789.504
202407 11,147.543 122.560 11,681.463
202410 12,667.512 121.956 13,339.952
202501 13,554.473 121.473 14,330.753
202504 16,151.523 123.888 16,743.659
202507 17,594.622 124.613 18,133.618
202510 20,029.994 125.410 20,512.337
202601 20,195.720 124.690 20,801.478
202604 21,185.726 128.430 21,185.726

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ARS10,347.34 mean?
Medtronic (BUE:MDT) has a Cyclically Adjusted Revenue per Share of ARS10,347.34 as of Apr. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medtronic and its competitors.
Is Medtronic's Cyclically Adjusted Revenue per Share too high?
Medtronic's current Cyclically Adjusted Revenue per Share is ARS10,347.34. Overall, Medtronic has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Cyclically Adjusted Revenue per Share compare to SYK and BSX?
Medtronic's Cyclically Adjusted Revenue per Share of ARS10,347.34 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medtronic and its competitors. Medtronic's current Cyclically Adjusted Revenue per Share is ARS10,347.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BUE:MDT) is currently considered Modestly Undervalued. The stock's GF Value™ is ARS38,174.99, compared to a current price of ARS32,520.00 — trading 14.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ARS10,347.34. Medtronic's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medtronic (BUE:MDT), the current Cyclically Adjusted Revenue per Share is ARS10,347.34 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medtronic (BUE:MDT) Overvalued in 2026?

Based on GuruFocus' analysis, Medtronic stock appears to be undervalued. The current stock price of ARS32,520.00 is trading 14.8% below its estimated GF Value™ of ARS38,174.99. GuruFocus considers Medtronic to be Modestly Undervalued.

Key valuation signals for BUE:MDT:

  • Cyclically Adjusted Revenue per Share: ARS10,347.34
  • GF Value™: ARS38,174.99 vs. price of ARS32,520.00 (14.8% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the BUE:MDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medtronic Business Description

Address Parkmore Business Park West, Building Two, Galway, IRL
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
66GF Score

Get the complete analysis for BUE:MDT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS32,520.00
Price
ARS38,174.99
GF Value